Transplantation algorithm for myelofibrosis in 2022 and beyond
Tóm tắt
Từ khóa
Tài liệu tham khảo
Tefferi, 2015, Myeloproliferative neoplasms: a contemporary review, JAMA Oncol, 1, 97, 10.1001/jamaoncol.2015.89
Nangalia, 2017, Myeloproliferative neoplasms: from origins to outcomes, Blood, 130, 2475, 10.1182/blood-2017-06-782037
Vainchenker, 2017, Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms, Blood, 129, 667, 10.1182/blood-2016-10-695940
Hultcrantz, 2020, Incidence of myeloproliferative neoplasms - trends by subgroup and age in a population-based study in Sweden, J Intern Med, 287, 448, 10.1111/joim.13019
Pastor-Galan, 2020, Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis, Med Clin (Barc), 155, 152
Cervantes, 2012, Improving survival trends in primary myelofibrosis: an international study, J Clin Oncol, 30, 2981, 10.1200/JCO.2012.42.0240
Tefferi, 2012, One thousand patients with primary myelofibrosis: the mayo clinic experience, Mayo Clin Proc, 87, 25, 10.1016/j.mayocp.2011.11.001
Masarova, 2022, Improved survival of patients with myelofibrosis in the last decade: single-center experience, Cancer, 128, 1658, 10.1002/cncr.34103
Kroger, 2015, Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group, Leukemia, 29, 2126, 10.1038/leu.2015.233
Masarova, 2017, Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis, Leuk Res, 59, 110, 10.1016/j.leukres.2017.06.001
Tam, 2009, Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis, J Clin Oncol, 27, 5587, 10.1200/JCO.2009.22.8833
Cervantes, 2009, New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment, Blood, 113, 2895, 10.1182/blood-2008-07-170449
Penna, 2019, 20+ Years and alive with primary myelofibrosis: phenotypic signature of very long-lived patients, Am J Hematol, 94, 286, 10.1002/ajh.25351
Guglielmelli, 2017, Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis, Blood, 10.1182/blood-2017-01-761999
Hultcrantz, 2015, Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in Sweden between 1973 and 2005: a population-based study, J Clin Oncol, 33, 2288, 10.1200/JCO.2014.57.6652
Bewersdorf, 2021, Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis-A systematic review and meta-analysis, Transplant Cell Ther, 27, 873, 10.1016/j.jtct.2021.05.016
Robin, 2019, Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis, Haematologica, 104, 1782, 10.3324/haematol.2018.205211
Barbui, 2018, Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet, Leukemia, 32, 1057, 10.1038/s41375-018-0077-1
Kroger, 2015, Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis, Blood, 125, 3347, 10.1182/blood-2014-10-608315
Gowin, 2020, Survival following allogeneic transplant in patients with myelofibrosis, Blood Adv, 4, 1965, 10.1182/bloodadvances.2019001084
Cipkar, 2022, Optimal timing of allogeneic stem cell transplantation for primary myelofibrosis, Transplant Cell Ther, 28, 189, 10.1016/j.jtct.2022.01.018
Hernandez-Boluda, 2016, Predictive factors for anemia response to erythropoiesis stimulating agents in myelofibrosis, Eur J Haematol
Masarova, 2018, Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis, Eur J Haematol, 100, 257, 10.1111/ejh.13005
Hernandez-Boluda, 2021, Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: a study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry, Am J Hematol, 96, 1186, 10.1002/ajh.26279
Alchalby, 2014, Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the myeloproliferative neoplasm subcommittee of the CMWP of the European group for blood and marrow transplantation, Biol Blood Marrow Transplant, 20, 279, 10.1016/j.bbmt.2013.10.027
Cahu, 2014, Allo-SCT for Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC), Bone Marrow Transplant, 49, 756, 10.1038/bmt.2014.31
Hernandez-Boluda, 2022, Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: a series of 372 patients from the PETHEMA AML registry, Leuk Res, 115, 106821, 10.1016/j.leukres.2022.106821
Gupta, 2020, Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phase, Blood Adv, 4, 5562, 10.1182/bloodadvances.2020002727
Passamonti, 2008, A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis, Blood, 111, 3383, 10.1182/blood-2007-11-121434
Gangat, 2011, DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status, J Clin Oncol, 29, 392, 10.1200/JCO.2010.32.2446
Passamonti, 2017, A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis, Leukemia, 10.1038/leu.2017.169
Guglielmelli, 2018, MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis, J Clin Oncol, 36, 310, 10.1200/JCO.2017.76.4886
Tefferi, 2018, MIPSS70+ version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis, J Clin Oncol, 36, 1769, 10.1200/JCO.2018.78.9867
Tefferi, 2018, GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis, Leukemia, 32, 1631, 10.1038/s41375-018-0107-z
Grinfeld, 2018, Classification and personalized prognosis in myeloproliferative neoplasms, N Engl J Med, 379, 1416, 10.1056/NEJMoa1716614
How, 2020, A practical guide for using myelofibrosis prognostic models in the clinic, J Natl Compr Cancer Netw, 18, 1271, 10.6004/jnccn.2020.7557
Hernandez-Boluda, 2018, Prognostic risk models for transplant decision-making in myelofibrosis, Ann Hematol, 97, 813, 10.1007/s00277-018-3240-x
Hernandez-Boluda, 2018, Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis, Leukemia, 32, 553, 10.1038/leu.2017.297
Tefferi, 2014, Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis, Blood, 124, 2507, 10.1182/blood-2014-05-579136
Passamonti, 2010, Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis, Blood, 116, 2857, 10.1182/blood-2010-06-293415
Palandri, 2020, Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: real-world data, Hematol Oncol, 38, 372, 10.1002/hon.2737
Vallapureddy, 2019, Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model, Blood Cancer J, 9, 12, 10.1038/s41408-019-0175-y
Masarova, 2020, Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era, Cancer, 126, 4322, 10.1002/cncr.33094
Gagelmann, 2022, Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis, Blood Adv, 6, 1222, 10.1182/bloodadvances.2021006827
Gagelmann, 2019, Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation, Blood, 133, 2233, 10.1182/blood-2018-12-890889
Hernandez-Boluda, 2020, Predicting survival after allogeneic hematopoietic cell transplantation in myelofibrosis: performance of the myelofibrosis transplant scoring system (MTSS) and development of a new prognostic model, Biol Blood Marrow Transplant, 26, 2237, 10.1016/j.bbmt.2020.07.022
Smith, 2021, Association of factors influencing selection of upfront hematopoietic cell transplantation versus nontransplantation therapies in myelofibrosis, Transplant Cell Ther, 27, 600, 10.1016/j.jtct.2021.03.027
Palmer, 2019, Patient perspectives regarding allogeneic bone marrow transplantation in myelofibrosis, Biol Blood Marrow Transplant, 25, 398, 10.1016/j.bbmt.2018.09.033
McLornan, 2021, Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis, Bone Marrow Transplant, 56, 2160, 10.1038/s41409-021-01305-x
Davidson, 2021, Application of stem cell therapy in myelofibrosis, Hematol Oncol Clin N Am, 35, 391, 10.1016/j.hoc.2020.12.004
Polverelli, 2020, Am J Hematol
Harrison, 2012, JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis, N Engl J Med, 366, 787, 10.1056/NEJMoa1110556
Pardanani, 2015, Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial, JAMA Oncol, 1, 643, 10.1001/jamaoncol.2015.1590
Mesa, 2017, Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial, Lancet Haematol, 4, e225, 10.1016/S2352-3026(17)30027-3
Verstovsek, 2017, Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial, J Hematol Oncol, 10, 55, 10.1186/s13045-017-0417-z
Hernandez-Boluda, 2021, Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation, Leukemia, 35, 215, 10.1038/s41375-020-0815-z
Shanavas, 2016, Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to Janus kinase 1/2 inhibitors, Biol Blood Marrow Transplant, 22, 432, 10.1016/j.bbmt.2015.10.005
Kroger, 2021, Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT, Leukemia, 35, 3551, 10.1038/s41375-021-01276-4
Palandri, 2021, Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis, Blood Cancer J, 11, 4, 10.1038/s41408-020-00392-1
Kroger, 2018, Peritransplantation ruxolitinib prevents acute graft-versus-host disease in patients with myelofibrosis undergoing allogenic stem cell transplantation, Biol Blood Marrow Transplant, 24, 2152, 10.1016/j.bbmt.2018.05.023
Morozova, 2021, A prospective pilot study of graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and ruxolitinib in patients with myelofibrosis, Acta Haematol, 144, 158, 10.1159/000506758
Ali, 2022, Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study, Blood Adv, 6, 1444, 10.1182/bloodadvances.2021005035
Robin, 2017, The impact of splenectomy in myelofibrosis patients before allogeneic hematopoietic stem cell transplantation, Biol Blood Marrow Transplant, 23, 958, 10.1016/j.bbmt.2017.03.002
Ponce, 2022, Pretransplant splenic irradiation in patients with myeloproliferative neoplasms, Adv Radiat Oncol, 7, 100964, 10.1016/j.adro.2022.100964
Kalman, 2017, Low-dose splenic irradiation prior to hematopoietic cell transplantation in hypersplenic patients with myelofibrosis, Leuk Lymphoma, 58, 2983, 10.1080/10428194.2017.1321747
Helbig, 2019, Splenic irradiation before allogeneic stem cell transplantation for myelofibrosis, Med Oncol, 36, 16, 10.1007/s12032-019-1245-5
Tefferi, 2018, Blast phase myeloproliferative neoplasm: mayo-AGIMM study of 410 patients from two separate cohorts, Leukemia, 32, 1200, 10.1038/s41375-018-0019-y
Odenike, 2018, How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms, Blood, 132, 2339, 10.1182/blood-2018-03-785907
Gupta, 2014, Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research, Biol Blood Marrow Transplant, 20, 89, 10.1016/j.bbmt.2013.10.018
Murata, 2019, Comparison of outcomes of allogeneic transplantation for primary myelofibrosis among hematopoietic stem cell source groups, Biol Blood Marrow Transplant, 25, 1536, 10.1016/j.bbmt.2019.02.019
Raj, 2019, Family mismatched allogeneic stem cell transplantation for myelofibrosis: report from the chronic malignancies working party of European society for blood and marrow transplantation, Biol Blood Marrow Transplant, 25, 522, 10.1016/j.bbmt.2018.10.017
Jain, 2022, Post-transplantation cyclophosphamide-based graft- versus-host disease prophylaxis with nonmyeloablative conditioning for blood or marrow transplantation for myelofibrosis, Transplant Cell Ther, 28, 259, 10.1016/j.jtct.2022.02.004
Kunte, 2022, Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study, Leukemia, 36, 856, 10.1038/s41375-021-01449-1
Robin, 2011, Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC), Br J Haematol, 152, 331, 10.1111/j.1365-2141.2010.08417.x
McLornan, 2021, Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party, Leukemia, 35, 2445, 10.1038/s41375-021-01294-2
Hart, 2016, Splenic pooling and loss of VCAM-1 causes an engraftment defect in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation, Haematologica, 101, 1407, 10.3324/haematol.2016.146811
Czerw, 2022, Impact of donor-derived CD34 + infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT, Bone Marrow Transplant, 57, 261, 10.1038/s41409-021-01540-2
Cyriac, 2021, Effect of pre-transplant JAK1/2 inhibitors and CD34 dose on transplant outcomes in myelofibrosis, Eur J Haematol, 107, 517, 10.1111/ejh.13689
McLornan, 2019, Myeloablative and reduced-intensity conditioned allogeneic hematopoietic stem cell transplantation in myelofibrosis: a retrospective study by the chronic malignancies working party of the European society for blood and marrow transplantation, Biol Blood Marrow Transplant, 25, 2167, 10.1016/j.bbmt.2019.06.034
Robin, 2016, Outcome after transplantation according to reduced-intensity conditioning regimen in patients undergoing transplantation for myelofibrosis, Biol Blood Marrow Transplant, 22, 1206, 10.1016/j.bbmt.2016.02.019
Battipaglia, 2021, Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT, Bone Marrow Transplant, 56, 1593, 10.1038/s41409-021-01222-z
Claudiani, 2016, Treosulfan based reduced toxicity conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis, Hematol Oncol, 34, 154, 10.1002/hon.2183
Atagunduz, 2020, Treosulfan-based conditioning regimen for second allograft in patients with myelofibrosis, Cancers (Basel), 12, 10.3390/cancers12113098
Alchalby, 2016, Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis, Bone Marrow Transplant, 51, 1223, 10.1038/bmt.2016.98
Tamari, 2015, Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?, Bone Marrow Transplant, 50, 628, 10.1038/bmt.2014.323
Klyuchnikov, 2012, Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting, Br J Haematol, 159, 172, 10.1111/bjh.12013
Klyuchnikov, 2014, CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies, Biol Blood Marrow Transplant, 20, 382, 10.1016/j.bbmt.2013.11.034